SAFETY AND EFFICACY OF MEDICINAL CANNABIS IN ELDERLY PATIENTS: A RETROSPECTIVE REVIEW IN A NEUROLOGICAL OUTPATIENT SETTING.
Vincent Bargnes, Paul Hart, Sheila Gupta, Laszlo Mechtler
71st AAN Annual Meeting Abstract, American Academy of Neurology, February 2019
The aim of this randomised, survey-based study on patients aged 75+ was to assess the effects and safety of medicinal cannabis in elderly patients. The results show that medicinal cannabis is a well-tolerated treatment that can assist with chronic pain, sleep, neuropathy, and anxiety in patients aged 75+. However, authors suggest that further studies are required to investigate optimal dosing, tolerability and efficacy.
Pre-clinical studies documenting the anti-cancer effects of THC and its success in inhibiting cancer growth and spread have been on the rise. Clinical studies however are scarce as the psychoactive effects of THC can limit its medicinal and clinical use. Could non-psychoactive cannabinoids found in cannabis and hemp be the answer to treating cancer instead?
At ANTG, we are uniquely well-positioned to supply the domestic market and become the first medicinal cannabis company in Australia to export cannabis flower for commercial purposes to the EU. Interested in investing in medicinal cannabis? Read what sets ANTG apart.